Mylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever

Mylan always has been committed to providing people with access to more affordable medicines, and years ago made a commitment to stem the tide of HIV/AIDS by bringing to bear its ability to innovate, commitment to quality and growing manufacturing scale to help the people who most need it, no matter where they are or who they are.

"At Mylan, we view every day of every year as an opportunity to stem the disease's tide," commented Mylan CEO Heather Bresch. "Mylan's ARV products now are used by approximately half of everyone on the planet who is receiving treatment for HIV/AIDS. So it's important that we continue to invest and to leverage the millions of dollars we already have invested over the past several years to scale up our portfolio and ARV manufacturing capacities."

Mylan is one of the world's leading providers of HIV/AIDS medicines and strives to meet global demand with a reliable supply of affordable medications. Its portfolio currently contains 16 active pharmaceutical ingredients (API) and 50 finished dosage forms. Mylan continues to invest in R&D and operations to keep pace and stay ahead in providing the comprehensive basket of vertically integrated and affordable quality drug products for the future.

"Mylan has a long tradition of innovation, and we're not standing still," said Mylan President Rajiv Malik. "We have more than 3,000 scientists worldwide, many of them dedicated to our ARV franchise, working to develop innovative solutions to satisfy unmet needs. Their skill and dedication allowed us to submit an application in March 2016 to the U.S. Food and Drug Administration for a reduced-dose version of the world's most commonly used ARV combination drug, Tenofovir Disoproxil Fumarate + Lamivudine + Efavirenz."

Mylan's version, which uses one-third less Efavirenz, is formulated to be as effective as the original version. If approved, the company believes it will improve the side effect profile and also will save payers money by requiring less API in each tablet, a meaningful change for a product now used by more than 5.5 million people each year.

Over the next twelve months, Mylan expects to submit several more applications for innovative ARVs that will help push down costs while continuing to improve patients' well-being.

Mylan also continues to build on its highly successful and important work over the years in serving "access markets." These markets comprise approximately 100 developing countries in which brand producers of ARVs license or otherwise permit competition by generics to help make sure these more affordable alternatives are available to people with limited incomes. Specifically, Mylan now is bringing its passion for meeting unmet needs to middle- and higher-income markets as well, including the U.S. and Europe.

Mylan encourages everyone to observe World AIDS Day and make a commitment to address the scourge of HIV/AIDS. There are many ways to help. One place to start is by learning more about the disease, including its routes of transmission. Organizations such as UNAIDS and the World Health Organization are great resources people can use to learn and share information with family, friends or neighbors.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS worldwide depend. We market our products in more than 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 40,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to product submissions and expectations, markets for products, investments, product capacity, and Mylan's strategy.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to:  any changes in or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; risks associated with international operations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

Logo - http://photos.prnewswire.com/prnh/20140423/77793

SOURCE Mylan N.V.

Related Links

http://www.mylan.com